Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative
- PMID: 25988241
- PMCID: PMC4551571
- DOI: 10.1002/art.39198
Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative
Abstract
Objective: To evaluate the incidence of cardiovascular disease (CVD) morbidity and mortality over the course of 10 years among the more than 160,000 postmenopausal women in the Women's Health Initiative (WHI) in relation to self-reported rheumatoid arthritis (RA), taking disease-modifying antirheumatic drugs (DMARDs), anti-cyclic citrullinated peptide (anti-CCP) positivity, rheumatoid factor (RF) positivity, CVD risk factors, joint pain, and inflammation (white blood cell count and interleukin-6 levels).
Methods: Anti-CCP and RF were measured in a sample of WHI participants with self-reported RA (n = 9,988). RA was classified as self-reported RA plus anti-CCP positivity and/or taking DMARDs. Anti-CCP-negative women with self-reported RA and not taking DMARDs were classified as having "unverified RA."
Results: Age-adjusted rates of coronary heart disease (CHD), stroke, CVD, fatal CVD, and total mortality were higher in women with RA than in women with no reported RA, with multivariable-adjusted hazard ratios of 1.46 (95% confidence interval [95% CI] 1.17-1.83) for CHD and 2.55 (95% CI 1.86-3.51) for fatal CVD. Among women with RA, anti-CCP positivity and RF positivity were not significantly associated with higher risk of any outcomes, despite slightly higher risk of death for those who were anti-CCP positive than for those who were anti-CCP negative. Joint pain severity and CVD risk factors were strongly associated with CVD risk, even in women with no reported RA. CVD incidence was increased in women with RA versus women with no reported RA at almost all risk factor levels, except for low levels of joint pain or inflammation. Among women with RA, inflammation was more strongly associated with fatal CVD and total mortality than with CHD or CVD.
Conclusion: Among postmenopausal women, RA was associated with 1.5-2.5-fold higher CVD risk. CVD risk was strongly associated with CVD risk factors, joint pain severity, and inflammation, but not with anti-CCP positivity or RF positivity.
© 2015, American College of Rheumatology.
Figures
Comment in
-
Reply.Arthritis Rheumatol. 2016 Feb;68(2):555-6. doi: 10.1002/art.39471. Arthritis Rheumatol. 2016. PMID: 26473508 No abstract available.
-
Cardiovascular Events in Rheumatoid Arthritis-Time to See Beyond Articular Involvement in "Real World" Clinical Practice: Comment on the Article by Mackey et al.Arthritis Rheumatol. 2016 Feb;68(2):554-5. doi: 10.1002/art.39467. Arthritis Rheumatol. 2016. PMID: 26474273 No abstract available.
References
-
- Meune C, Touze E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010;103(4):253–61. - PubMed
-
- Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690–7. - PubMed
-
- Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107(9):1303–7. - PubMed
-
- Bergstrom U, Jacobsson LT, Turesson C. Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmo, Sweden. Rheumatology (Oxford) 2009;48(12):1600–5. - PubMed
-
- Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine. 2011;78(2):179–83. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01-WH-32118/WH/WHI NIH HHS/United States
- N01-WH-42129-32/WH/WHI NIH HHS/United States
- N01-WH-32115/WH/WHI NIH HHS/United States
- N01-WH-32108-9/WH/WHI NIH HHS/United States
- HHSN268201100003C/WH/WHI NIH HHS/United States
- N01-WH-42107-26/WH/WHI NIH HHS/United States
- HHSN268200900006C/WH/WHI NIH HHS/United States
- HHSN268201100002C/WH/WHI NIH HHS/United States
- N01-WH-44221/WH/WHI NIH HHS/United States
- N01-WH-32122/WH/WHI NIH HHS/United States
- HHSN268201100004C/WH/WHI NIH HHS/United States
- N01-WH-24152/WH/WHI NIH HHS/United States
- HHSN268201100046C/HL/NHLBI NIH HHS/United States
- N01 WH022110/WH/WHI NIH HHS/United States
- N01-WH-32105-6/WH/WHI NIH HHS/United States
- HHSN271201100004C/AG/NIA NIH HHS/United States
- HHSN268200960006C/PHS HHS/United States
- N01-WH-22110/WH/WHI NIH HHS/United States
- N01-WH-32119/WH/WHI NIH HHS/United States
- N01-WH-32111-13/WH/WHI NIH HHS/United States
- N01-WH-32100-2/WH/WHI NIH HHS/United States
- HHSN268201100001C/WH/WHI NIH HHS/United States
LinkOut - more resources
Medical